LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of investors of Endo International plc (“Endo International” or the “Company”) (NASDAQ: ENDP) concerning the Company and its officers’ possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors.
Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide.
On May 5, 2016, Endo International lowered its 2016 forecasts, citing “previously unanticipated headwinds,” including the “loss of exclusivity” for its Voltaren Gel medicine, “increasing competition,” and delays on regulatory actions. On this news the Company’s shares fell sharply in value.
If you purchased Endo International securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.